Century Therapeutics Narrows Quarterly Loss to $23.5M
The Philadelphia-based biotech reported lower research spending as it advances its type 1 diabetes cell therapy toward clinical trials.
Updated on Nov. 20, 2026 in Healthcare

Century Therapeutics reported a third-quarter net loss of $23.5 million, a 32% reduction from $34.4 million in the comparable 2025 quarter. The company ended September with $174.1 million in cash, cash equivalents and investments.
Why it matters
The narrower loss reflects a restructuring of Century's development priorities that cut personnel and facility costs. Its cash runway, projected into the first quarter of 2029, will shape how far its lead diabetes program can advance before the company needs additional funding.
Research and development expenses fell to $18.1 million from $22.5 million, while general and administrative expenses rose slightly to $7.1 million from $6.8 million. Cash, cash equivalents and investments stood at $174.1 million at September's end, up from $117.1 million at the end of 2025, and the company did not explain the source of that increase.
The players
Century Therapeutics Inc.
Century Therapeutics is a Philadelphia-based biotechnology company developing induced pluripotent stem cell therapies for autoimmune disease, cancer and diabetes.
Joseph Truitt
Joseph Truitt is an executive and board member who was appointed to Century Therapeutics' board of directors during the quarter.
The details
Century Therapeutics is developing CNTY-813, an investigational islet cell replacement therapy for type 1 diabetes that uses induced pluripotent stem cells engineered to produce insulin-secreting islet cells. Nonclinical results showed the therapy restored normal blood glucose levels in diabetic mice, and the company reached general alignment with the FDA on its testing package, manufacturing process and proposed Phase 1/2 trial design.
Timeline
2025: Comparable quarter net loss of $34.4 million reported.
September 2026: Century ended the quarter with $174.1 million in cash and investments.
Fourth quarter of 2026: Planned IND submission for CNTY-813 to the FDA.
Second half of 2027: Initial clinical safety and efficacy data for CNTY-813 anticipated.
First quarter of 2029: Projected end of cash runway.
Market Landscape
Century's islet cell program is moving through the same stem-cell-derived diabetes pathway that other developers have pursued to reach clinical testing. Its narrowed loss and pending IND submission place it among the biotechs trying to convert iPSC platforms into the first approved cell-replacement treatments for type 1 diabetes.
For people living with type 1 diabetes, CNTY-813 remains investigational and is not yet available, and the planned trial's first safety and efficacy data are not expected until the second half of 2027. Patients and families should continue current treatment plans and discuss any clinical trial enrollment with their physicians.
The takeaway
Century's narrowed loss shows how biotech companies trim spending to extend cash runways while they wait for early clinical data. Watch the company's planned IND filing and 2027 trial readouts to judge whether the islet cell approach moves closer to patients.
Further reading
Explore more Healthcare coverage to see how biotech pipelines like this one are reshaping treatment options in Philadelphia.
Source note: This article includes information reported by MyChesCo.






